This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Janssen Pharmaceutica Nv, Protagonist Therapeutics, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2,101 
1 out of 35 
Years Active: 2024
Title: Shu Li - Innovator in Autoimmune Treatment
Introduction
Shu Li is a notable inventor based in Newark, CA (US). He has made significant contributions to the field of autoimmune inflammation through his innovative research and development of peptide inhibitors.
Latest Patents
Shu Li holds 1 patent for his invention titled "Compositions of peptide inhibitors of Interleukin-23 receptor." This invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof. It also includes corresponding pharmaceutical compositions, methods, and uses for the treatment of autoimmune inflammation and related diseases and disorders.
Career Highlights
Throughout his career, Shu Li has worked with prominent companies in the pharmaceutical industry, including Janssen Pharmaceutica and Protagonist Therapeutics, Inc. His work has been instrumental in advancing therapeutic options for patients suffering from autoimmune conditions.
Collaborations
Shu Li has collaborated with several professionals in his field, including Giustino Di Pretoro and Dajun Sun. Their combined expertise has contributed to the success of his research and innovations.
Conclusion
Shu Li's work in developing peptide inhibitors for autoimmune treatment showcases his dedication to improving healthcare solutions. His contributions are paving the way for advancements in the treatment of autoimmune diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile